◎ Sugi Atlas

Atlas / Drug / Icatibant

Icatibant

drug
On this page

Also known as IcatibantoHOE-140[DArg0Hyp3Thi5D-Tic 7Oic8]bradykinin

Summary

Icatibant (CHEMBL2028850) is an approved protein β-adrenergic antagonist (ATC B06AC02) targeting BDKRB1 and BDKRB2; indicated across 8 conditions including angioedema and hereditary angioedema.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: B06AC02
  • Targets: 2 (BDKRB1, BDKRB2)
  • Indications: 8 conditions
  • Clinical trials: 20
  • Chemistry: 1304.5 Da · C59H89N19O13S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2028850
NameIcatibant
TypeProtein
Max phase4
FDA approvedyes
PubChem CID6918173
ChEBICHEBI:68556
ATCB06AC02
Molecular formulaC59H89N19O13S
Molecular weight1304.5
InChIKeyQURWXBZNHXJZBE-SKXRKSCCSA-N

SMILES: C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O

IUPAC name: (2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid

ChEBI definition: A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.

Pharmacological roles (ChEBI): peptidomimetic, β-adrenergic antagonist, bradykinin receptor antagonist.

Also known as: Icatibant, Icatibanto, HOE-140, [DArg0, Hyp3, Thi5, D-Tic 7, Oic8]bradykinin, ICATIBANT

Parent form; salt/anhydrous children: CHEMBL2028852

Patent coverage: 39 distinct patent families (108 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 103 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
BDKRB1B1 receptorAntagonist70%P46663
BDKRB2B2 receptorAntagonist8.40.2%P30411

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: B2 bradykinin receptor, B2 bradykinin receptor, B2 bradykinin receptor, Mas-related G-protein coupled receptor member X2.

Bioactivity

ChEMBL activities: 20 potent at pChembl ≥ 5 of 21 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
BDKRB210.6Ki0.03nMCHEMBL_ACT_1709742
BDKRB210.22Ki0.06nMCHEMBL_ACT_675135
BDKRB210.19Ki0.06nMCHEMBL_ACT_63692
P2502310.11Ki0.08nMCHEMBL_ACT_63693
O7052610.05IC500.09nMCHEMBL_ACT_176156
O7052610.05IC500.09nMCHEMBL_ACT_190110
O7052610.05IC500.09nMCHEMBL_ACT_822248
O705269.96Ki0.11nMCHEMBL_ACT_416564
BDKRB29.74Ki0.18nMCHEMBL_ACT_902557
BDKRB29.55Kd0.28nMCHEMBL_ACT_1709744
P250239.5Kd0.32nMCHEMBL_ACT_902553
BDKRB29.31IC500.49nMCHEMBL_ACT_176158
BDKRB29.31IC500.49nMCHEMBL_ACT_822249
BDKRB29.1Ki0.79nMCHEMBL_ACT_25090665
BDKRB29.04Kd0.91nMCHEMBL_ACT_271632
BDKRB28.97IC501.07nMCHEMBL_ACT_25500430
O705268.97IC501.07nMCHEMBL_ACT_498917
BDKRB28.48IC503.3nMCHEMBL_ACT_176157
BDKRB28.48IC503.3nMCHEMBL_ACT_190111
O705268.27IC505.4nMCHEMBL_ACT_498918

Target pathways

Aggregated over 2 target gene(s): BDKRB1, BDKRB2.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction2BDKRB1, BDKRB2
Signaling by GPCR2BDKRB1, BDKRB2
Class A/1 (Rhodopsin-like receptors)2BDKRB1, BDKRB2
Peptide ligand-binding receptors2BDKRB1, BDKRB2
GPCR downstream signalling2BDKRB1, BDKRB2
G alpha (q) signalling events2BDKRB1, BDKRB2
G alpha (i) signalling events2BDKRB1, BDKRB2
GPCR ligand binding2BDKRB1, BDKRB2

Dominant GO biological processes

GO termTargets
inflammatory response2
G protein-coupled receptor signaling pathway2
positive regulation of cytosolic calcium ion concentration2
signal transduction2
positive regulation of leukocyte migration1
response to mechanical stimulus1
cell migration1
negative regulation of cell growth1
response to lipopolysaccharide1
negative regulation of blood pressure1
positive regulation of release of sequestered calcium ion into cytosol1
smooth muscle contraction1
cell surface receptor signaling pathway1
cell surface receptor protein tyrosine kinase signaling pathway1
blood circulation1

Indications & clinical

Indications

7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
angioedema3MONDO:0010481EFO:0005532
hereditary angioedema3MONDO:0019623MONDO:0019623
hypotensive disorder3MONDO:0005468EFO:0005251
heart failure2MONDO:0005252EFO:0003144
arthropathy2MONDO:0006816EFO:1000999
severe acute respiratory syndrome2MONDO:0005091EFO:0000694
inborn mitochondrial metabolism disorder2MONDO:0004069MONDO:0044970

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

PhaseTrials
PHASE38
PHASE25
PHASE43
PHASE12
PHASE2/PHASE31
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01457430PHASE4COMPLETEDEfficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
NCT01574248PHASE4TERMINATEDEffect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
NCT04113109PHASE4COMPLETEDMechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
NCT05834777PHASE3RECRUITINGPrevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
NCT00097695PHASE3COMPLETEDSubcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
NCT00500656PHASE3COMPLETEDSubcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
NCT00912093PHASE3COMPLETEDA Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
NCT00997204PHASE3COMPLETEDEASSI - Evaluation of the Safety of Self-Administration With Icatibant
NCT01386658PHASE3COMPLETEDA Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
NCT01919801PHASE3COMPLETEDBlinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
NCT03888755PHASE3COMPLETEDA Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
NCT05407597PHASE2/PHASE3COMPLETEDInhibition of Bradykinin in COVID-19 Infection With Icatibant
NCT04488081PHASE2ACTIVE_NOT_RECRUITINGI-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT00303056PHASE2COMPLETEDEfficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis
NCT03005184PHASE2WITHDRAWNMechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
NCT03177798PHASE2COMPLETEDMitochondria and Chronic Kidney Disease
NCT05010876PHASE2COMPLETEDEvaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
NCT00517582PHASE1TERMINATEDBradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema
NCT02045264PHASE1COMPLETEDOpen-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
NCT05509569Not specifiedCOMPLETEDA Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

217 molecules share ≥1 primary target. Top 100 by shared-target count:

MoleculeSourceStatusShared targets
RIFAMPINChEMBL + PubChemPhase 4 (approved)BDKRB1, BDKRB2
TamoxifenChEMBL + PubChemPhase 4 (approved)BDKRB1, BDKRB2
AcetylcholinePubChemApprovedBDKRB1, BDKRB2
Aclidinium BromidePubChemApprovedBDKRB1, BDKRB2
AcyclovirPubChemApprovedBDKRB1, BDKRB2
Alendronic AcidPubChemApprovedBDKRB1, BDKRB2
AllopurinolPubChemApprovedBDKRB1, BDKRB2
AlogliptinPubChemApprovedBDKRB1, BDKRB2
AlprazolamPubChemApprovedBDKRB1, BDKRB2
AmiloridePubChemApprovedBDKRB1, BDKRB2
AmitriptylinePubChemApprovedBDKRB1, BDKRB2
AmlodipinePubChemApprovedBDKRB1, BDKRB2
AmoxapinePubChemApprovedBDKRB1, BDKRB2
AspirinPubChemApprovedBDKRB1, BDKRB2
AzathioprinePubChemApprovedBDKRB1, BDKRB2
BaclofenPubChemApprovedBDKRB1, BDKRB2
BeclomethasonePubChemApprovedBDKRB1, BDKRB2
Beclomethasone DipropionatePubChemApprovedBDKRB1, BDKRB2
BicalutamidePubChemApprovedBDKRB1, BDKRB2
BisoprololPubChemApprovedBDKRB1, BDKRB2
BosentanPubChemApprovedBDKRB1, BDKRB2
BumetanidePubChemApprovedBDKRB1, BDKRB2
CaffeinePubChemApprovedBDKRB1, BDKRB2
CandesartanPubChemApprovedBDKRB1, BDKRB2
Candesartan CilexetilPubChemApprovedBDKRB1, BDKRB2
CarisoprodolPubChemApprovedBDKRB1, BDKRB2
CarvedilolPubChemApprovedBDKRB1, BDKRB2
ClozapinePubChemApprovedBDKRB1, BDKRB2
DesloratadinePubChemApprovedBDKRB1, BDKRB2
dexamethasonePubChemApprovedBDKRB1, BDKRB2
DihydroergotaminePubChemApprovedBDKRB1, BDKRB2
EthambutolPubChemApprovedBDKRB1, BDKRB2
FidaxomicinPubChemApprovedBDKRB1, BDKRB2
FludrocortisonePubChemApprovedBDKRB1, BDKRB2
MethotrexatePubChemApprovedBDKRB1, BDKRB2
NaproxenPubChemApprovedBDKRB1, BDKRB2
OlanzapinePubChemApprovedBDKRB1, BDKRB2
Olmesartan MedoxomilPubChemApprovedBDKRB1, BDKRB2
PhenytoinPubChemApprovedBDKRB1, BDKRB2
PimozidePubChemApprovedBDKRB1, BDKRB2
PropoxyphenePubChemApprovedBDKRB1, BDKRB2
PyrazinamidePubChemApprovedBDKRB1, BDKRB2
SildenafilPubChemApprovedBDKRB1, BDKRB2
SonidegibPubChemApprovedBDKRB1, BDKRB2
StavudinePubChemApprovedBDKRB1, BDKRB2
SulindacPubChemApprovedBDKRB1, BDKRB2
TegaserodPubChemApprovedBDKRB1, BDKRB2
theophyllinePubChemApprovedBDKRB1, BDKRB2
Tiotropium Bromide MonohydratePubChemApprovedBDKRB1, BDKRB2
ValacyclovirPubChemApprovedBDKRB1, BDKRB2
VerapamilPubChemApprovedBDKRB1, BDKRB2
AMIODARONEChEMBL + PubChemPhase 4 (approved)BDKRB2
AMSACRINEChEMBLPhase 4 (approved)BDKRB2
INDOCYANINE GREEN ACID FORMChEMBLPhase 4 (approved)BDKRB2
NILOTINIBChEMBLPhase 4 (approved)BDKRB1
NIMESULIDEChEMBLPhase 4 (approved)BDKRB2
NITAZOXANIDEChEMBLPhase 4 (approved)BDKRB2
PYRVINIUMChEMBLPhase 4 (approved)BDKRB2
RIFAXIMINChEMBLPhase 4 (approved)BDKRB2
SUNITINIBChEMBLPhase 4 (approved)BDKRB2
DIACEREINChEMBLPhase 3BDKRB2
BENZETHONIUMChEMBL + PubChemPhase 2 (approved)BDKRB2
ALPRENOLOLChEMBLPhase 2BDKRB2
BRADYKININChEMBLPhase 2BDKRB2
FASITIBANTChEMBLPhase 2BDKRB2
FASITIBANT CHLORIDEChEMBLPhase 2BDKRB2
LABRADIMILChEMBLPhase 2BDKRB2
MK0686ChEMBLPhase 2BDKRB1
SAFOTIBANTChEMBLPhase 2BDKRB1
AbirateronePubChemApprovedBDKRB2
AcebutololPubChemApprovedBDKRB2
AcetazolamidePubChemApprovedBDKRB2
acetylcysteinePubChemApprovedBDKRB2
AdeninePubChemApprovedBDKRB2
AfatinibPubChemApprovedBDKRB2
AlbendazolePubChemApprovedBDKRB2
albuterolPubChemApprovedBDKRB2
AlfuzosinPubChemApprovedBDKRB2
AlmotriptanPubChemApprovedBDKRB2
AlosetronPubChemApprovedBDKRB2
AmantadinePubChemApprovedBDKRB2
aminolevulinic acidPubChemApprovedBDKRB2
AmisulpridePubChemApprovedBDKRB2
AmoxicillinPubChemApprovedBDKRB1
AmphetaminePubChemApprovedBDKRB1
AnagrelidePubChemApprovedBDKRB2
AntipyrinePubChemApprovedBDKRB2
ApixabanPubChemApprovedBDKRB2
AprepitantPubChemApprovedBDKRB2
AtazanavirPubChemApprovedBDKRB2
AtenololPubChemApprovedBDKRB2
Azelaic AcidPubChemApprovedBDKRB2
BelzutifanPubChemApprovedBDKRB2
BenzocainePubChemApprovedBDKRB2
Betamethasone DipropionatePubChemApprovedBDKRB2
Betamethasone ValeratePubChemApprovedBDKRB2
BethanecholPubChemApprovedBDKRB2
BiotinPubChemApprovedBDKRB2
BrimonidinePubChemApprovedBDKRB2
BromocriptinePubChemApprovedBDKRB1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot